Phase IIIB Switching From Intravenous to Subcutaneous Study

PHASE3CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2012

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Abatacept

Subcutaneous injection, 125 mg/mL, once weekly, 48 months

Trial Locations (30)

12206

The Center For Rheumatology, Llp, Albany

14080

Local Institution, Mexico City

19090

Rheumatic Disease Associates, Ltd., Willow Grove

22320

Local Institution, Tijuana

28210

The Arthritis Clinic & Carolina Bone & Joint, Charlotte

28601

Unifour Medical Research, Hickory

33180

Arthritis & Rheumatic Disease Specialties, Aventura

35801

Rheumatology Associates Of N. Al, P.C., Huntsville

42101

Graves Gilbert Clinic, Bowling Green

44690

Local Institution, Guadalajara

45219

Cincinnati Rheumatic Disease Study Group, Cincinnati

46227

Diagnostic Rheumatology And Research,Pc, Indianapolis

64020

Local Institution, Nuevo León

68516

Physician Research Collaboration, Llc, Lincoln

75246

Arthritis Centers Of Texas, Dallas

78240

Local Institution, San Luis Potosí City

78705

Walter F. Chase, Md, Austin

89128

Innovative Health Research, Las Vegas

90806

Valerius Medical Group &Research Ctr. Of Greater Long Beach, Long Beach

91786

Inland Rheumatology Clinical Trials Inc., Upland

92037

Allergy & Rheumatology Medical Clinic, Inc., La Jolla

92260

Desert Medical Advances, Palm Desert

97035

Portland Rheumatology Clinic, Lake Oswego

T6G 2S2

Local Institution, Edmonton

A1A 5E8

Local Institution, St. John's

N2M 5N6

Local Institution, Kitchener

M5G 1X5

Local Institution, Toronto

H2L 1S6

Local Institution, Montreal

G1V 3M7

Local Institution, Québec

06726

Local Institution, Mexico City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY